Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 653 02 00

Website: www.adctherapeutics.com

Address:

BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

SamHot Mar. 12 at 3:03 PM

$ADCT opportunity to buy a little more

0 · Reply

Gabriel_DS Mar. 12 at 2:31 PM

$ADCT did I miss something? Don't say market

0 · Reply

fmalad Mar. 12 at 5:04 AM

$ADCT lotus 5 we go to 10 buyout before lotus 7 we go to 28. Buyout after lotus 7 we go 30-35. No partnership. Hedge fund owners want cash offer!

1 · Reply

scalpemfast Mar. 12 at 1:59 AM

$ADCT , $AMD, $NVDA ADCT needs to be on your screen . It’s growing !!!

0 · Reply

scalpemfast Mar. 12 at 1:56 AM

$ADCT let’s get over $5 and open it up a little. Get on the gas !!!⛽️

0 · Reply

scalpemfast Mar. 11 at 2:08 AM

$ADCT buyout

0 · Reply

scalpemfast Mar. 11 at 1:39 AM

$ADCT buyout coming

1 · Reply

Nerevarine Mar. 10 at 5:27 PM

$ADCT Finally some good price action for this stellar company been in this for a while

0 · Reply

Rox22 Mar. 10 at 1:16 PM

$ADCT good call. Revenues up, costs down (and projected to decrease as studies wrap up). Data looks to be on timeline. Biggest take is of data goes well the market share they predict is very conservative, 10% of second line patients, which is why they have as a mini therapy currently. If data is differentiating (which the current numbers are) could be much higher % of second treatment protocols and the 600M-1billion opportunity could be much higher. Smart they are conservative, but they will adjust once they get the actual top line data. Good call! Suggest you read the transcript if you are invested here.

1 · Reply

StocktwitsEarnings Mar. 10 at 12:06 PM

$ADCT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 86.21% YoY • Reported revenue of $23.06M up 36.36% YoY • ADC Therapeutics expects topline LOTIS-5 results in 2Q 2026, with full data for LOTIS-5 and LOTIS-7 by year-end 2026, and anticipates cash runway at least into 2028, supporting potential regulatory approval for LOTIS-5 in mid-2027.

0 · Reply

ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 7:30 AM EDT - 7 days ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Mar 3, 2026, 7:15 AM EST - 14 days ago

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Mar 2, 2026, 4:05 PM EST - 15 days ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Feb 24, 2026, 7:15 AM EST - 21 days ago

ADC Therapeutics to Participate in March Investor Conferences

Feb 23, 2026, 7:15 AM EST - 22 days ago

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

Jan 15, 2026, 4:15 PM EST - 2 months ago

ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 4:05 PM EST - 2 months ago

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Jan 8, 2026, 7:15 AM EST - 2 months ago

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 4:05 PM EST - 2 months ago

ADC Therapeutics Announces New Employee Inducement Grant

$ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript$

Dec 3, 2025, 10:53 AM EST - 3 months ago

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript

$ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 3, 2025, 7:30 AM EST - 3 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 2, 2025, 4:05 PM EST - 3 months ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Nov 10, 2025, 11:21 AM EST - 4 months ago

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 4 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 3, 2025, 7:15 AM EST - 4 months ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Oct 27, 2025, 7:15 AM EDT - 5 months ago

ADC Therapeutics to Present at November Investor Conferences

Oct 13, 2025, 7:30 AM EDT - 5 months ago

ADC Therapeutics Announces $60 Million Private Placement

Aug 27, 2025, 7:15 AM EDT - 7 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 12, 2025, 11:27 AM EDT - 7 months ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 7 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 5, 2025, 4:05 PM EDT - 8 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Jul 1, 2025, 4:05 PM EDT - 9 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jun 16, 2025, 7:15 AM EDT - 9 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 12, 2025, 6:45 AM EDT - 9 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:30 AM EDT - 9 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

May 15, 2025, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 12:36 PM EDT - 10 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 8:00 AM EDT - 10 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 7:45 AM EDT - 10 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 8, 2025, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Apr 28, 2025, 7:00 AM EDT - 11 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 1, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 11:17 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 25, 2025, 5:30 PM EDT - 1 year ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 24, 2025, 11:08 PM EDT - 1 year ago

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

Mar 20, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Jan 30, 2025, 7:15 AM EST - 1 year ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 12, 2024, 2:03 PM EST - 1 year ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Nov 9, 2024, 11:01 AM EST - 1 year ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

SamHot Mar. 12 at 3:03 PM

$ADCT opportunity to buy a little more

0 · Reply

Gabriel_DS Mar. 12 at 2:31 PM

$ADCT did I miss something? Don't say market

0 · Reply

fmalad Mar. 12 at 5:04 AM

$ADCT lotus 5 we go to 10 buyout before lotus 7 we go to 28. Buyout after lotus 7 we go 30-35. No partnership. Hedge fund owners want cash offer!

1 · Reply

scalpemfast Mar. 12 at 1:59 AM

$ADCT , $AMD, $NVDA ADCT needs to be on your screen . It’s growing !!!

0 · Reply

scalpemfast Mar. 12 at 1:56 AM

$ADCT let’s get over $5 and open it up a little. Get on the gas !!!⛽️

0 · Reply

scalpemfast Mar. 11 at 2:08 AM

$ADCT buyout

0 · Reply

scalpemfast Mar. 11 at 1:39 AM

$ADCT buyout coming

1 · Reply

Nerevarine Mar. 10 at 5:27 PM

$ADCT Finally some good price action for this stellar company been in this for a while

0 · Reply

Rox22 Mar. 10 at 1:16 PM

1 · Reply

StocktwitsEarnings Mar. 10 at 12:06 PM

0 · Reply

fmalad Mar. 10 at 4:45 AM

$ADCT earnings should be inline tomorrow. Maybe to the upside!

0 · Reply

Arcides Mar. 5 at 6:32 PM

$ADCT every breakout attempt on last month has failed miserably...

2 · Reply

CrackheadApparel Mar. 5 at 2:55 PM

$ADCT I firmly believe that this will be one of the last with a $4 price.

0 · Reply

fort_worth_Jason Mar. 2 at 9:50 PM

$ADCT ADC Therapeutics is clearing gearing up for expanded use. Good time to get stock options!

0 · Reply

fort_worth_Jason Mar. 2 at 7:00 PM

$ADCT I would not be surprised if ADC Therapeutics is purchased by another company prior to these results. Once the results are shared the company becomes significantly more valuable. I am confident that is why we are seeing some the recent events. Hold tight and load up more if you can.

0 · Reply

SamHot Feb. 25 at 7:41 PM

$ADCT buy buy N BUY

0 · Reply

Rox22 Feb. 23 at 5:05 PM

$ADCT @fort_worth_Jason The agreement today essential trades 225 Million in the buyout agreement for 9.8 Million warrants executable at $3.81 share price. In order for that to break even I’m showing a potential buyout share price would have to be at $22.89 making the market cap 2.8 Billion (the buyout would be north of 3B dude to debt/agreemnt liabilities). That would be a reasonable buyout but HealthCare Royalty might know it’s higher like your 5B estimate as to risk the 225M they would potentially want more upside. This could happen quick in the current market for deals. Let’s hope so! LFG!!! Would LOVE a multi-Billion dollar buyout!

1 · Reply

InfernoWyrm Feb. 23 at 4:19 PM

$SONM $USAR $EYPT $ADCT ^#^

0 · Reply

Rox22 Feb. 23 at 2:51 PM

$ADCT When and do how much is the question. Would think it would occur after the readouts of Lotus 5 & 7 later this year but this news announcement could be indicating much sooner. My thought was a 2-4B buyout in the long run. I would think they would have more leverage after the readouts but perhaps they have good suitors knocking right now on their door. Fingers crossed.

1 · Reply

Gabriel_DS Feb. 23 at 1:57 PM

$ADCT https://finance.yahoo.com/news/adc-therapeutics-announces-amended-healthcare-121500601.html

0 · Reply

fort_worth_Jason Feb. 23 at 12:42 PM

$ADCT ADC Therapies is going to be acquired. This affirms it.

0 · Reply

Doozio Feb. 21 at 6:38 PM

$ADCT 👁️ 👀 YO!! Let’s bang bro. 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	524.69M
Revenue (ttm)	70.84M
Net Income (ttm)	-157.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-175.30%
Debt to Equity Ratio	-0.62

Volume	526,400
Avg Vol	803,550
Day's Range	N/A - N/A
Shares Out	127.04M
Stochastic %K	9%
Beta	1.92
Analysts	Strong Sell
Price Target	$7.80